Development and validation of a prognostic staging system for primary plasma cell leukemia

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Existing risk models for multiple myeloma (MM) are inadequate for primary plasma cell leukemia (pPCL) patients.
• pPCL is a rare and distinct subtype of MM characterized by ≥5% circulating plasma cells (CPC).

Purpose of the Study:

• To develop and validate a novel staging system specifically for pPCL.
• To improve patient stratification and survival prediction in pPCL.

Main Methods:

• A multicenter retrospective study involving 340 pPCL patients (training cohort) and 80 patients (validation cohort).
• Evaluation of baseline characteristics and cytogenetic abnormalities using univariate and multivariate analyses.
• Genome-wide DNA and RNA sequencing to explore molecular underpinnings of clinical heterogeneity.

Main Results:

• Del(17p), t(4;14), and t(14;16) were identified as high-risk cytogenetic abnormalities (HRCAs) in pPCL.
• A staging system was developed using HRCA, elevated LDH, and thrombocytopenia, stratifying patients into Stages I, II, and III.
• The proposed staging system demonstrated superior accuracy (c-index 0.711) compared to existing models, with significant differences in median overall survival across stages.

Conclusions:

• A new pPCL-specific staging system based on LDH, thrombocytopenia, and cytogenetic abnormalities has been developed.
• This staging system offers improved prognostic stratification for pPCL patients.
• Further validation, especially in prospective settings, is recommended.